




In silico investigation of the binding of MCoTI-II plant defense knottin to the γ-NGF 
serine protease of the 7S nerve growth factor complex and biological activity of its NGF 
mimetic properties. 
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Nerve Growth Factor (NGF) induces neurotrophic effects primarily through the 
tropomyosin-related kinase receptor TrkA NGF. While trophic proteins hold promise for 
the treatment of neuronal injury and disease, use of NGF is limited by its large molecular 
weight, lack of permeability through the blood brain barrier and peripheral side effects. 
High throughput screening on > 1000 natural plant based substances using a PC-12 neurite 
outgrowth model found only a single NGF mimetic hit, the seed pit of bitter gourd 
Momordica cochinchinensis. Bioactivity guided fractioning of the M. cochinchinensis seed 
extract confirmed the active component to be a protein of approximately 17kD MW, and 
not of chemical nature. By a theoretical understanding, it has been shown that in vivo, NGF 
exists as an inactive high molecular weight complex known as 7S NGF, which comprises 
pairs of two serine proteinases α-NGF and γ-NGF, and the trypsin inhibitor β-NGF. Active 
NGF is comprised of the free β-NGF dimer. Here we use computational modeling, which 
demonstrates that MCoTI-II can bind stably to the serine protease γ-NGF within the 7S 
NGF complex. This interaction may inhibit 7S NGF complex formation, potentially 
freeing the active NFG protein, and may explain the neuritogenic NGF mimetic activity of 
M. cochinchinensis seed extract. Recombinant purified MCoTI-II tested in rat PC-12 cells 
grown on collagen failed to initiate outgrowth relative to the control. While theoretical 
dockings studies show a plausible hypothetical explanation for trophic effects, biological 




Nerve Growth Factor (NGF) is an endogenously produced polypeptide that promotes the 
differentiation, survival and repair of neurons in the central and peripheral nervous systems 
[1-3]. The active form of NGF is a homodimer of two 118 residue polypeptides, of which 
each contains three intermolecular disulphide bridges in a cystine-knot motif [4, 5]. Its 
neurotrophic effects are mediated through binding to two types of cell-surface receptors, 
the tropomyosin-related kinase receptor (Trk) TrkA, and the p75 neurotrophin receptor [6]. 
 
In vivo, NGF initially exists as a high molecular weight complex known as 7S NGF [7-11], 
which comprises the active neurotrophic factor β-NGF dimer (also known as NGF) and 
two proteinases α-NGF and γ-NGF dimers in the complex (Fig. 1A). The α- and γ-NGF 
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subunits are closely related Family S1 serine endopeptidases [12], with γ-NGF sharing 
37% identity and 69% similarity with bovine trypsin (Fig. S1).  
 
When β-NGF is complexed with 7S NGF, it is inhibited from binding to its cognate 
receptors and is thus, inactive [13, 14]. Additionally, α-NGF and γ-NGF both 
competitively block steady-state binding of β-NGF to PC12 cells [15]. These studies 
indicate that free β-NGF is active and in dynamic equilibrium with the inactive complexed 
form 7S NGF. Although trophic proteins such as NGF hold promise for the treatment of 
neuronal injury and disease [16-20], therapeutic applications have been limited by its lack 
of permeability through the blood brain barrier [21, 22]. In recent years an NGF mimetic 
has been shown to improve neuronal survival, differentiation, and synaptic plasticity, 
having relevance for Alzheimer's disease [23], Parkinson’s disease [24] and brain / spinal 
cord injury [25]. 
 
Previously, we discovered that an extract of the seed of the Momordica cochinchinensis 
exerted neurotrophic, NGF-mimetic effects in PC-12 cells [26]. While the molecular basis 
of this effect remains to be determined, the cystine-knot motif of NGF put us in mind of 
the MCoTI plant defense proteins, which similarly contain a cystine-knot that could bind 
with high affinity to Family S1 serine endopeptidases [27-29]. MCoTI-I and -II are found 
in the M. cochinchinensis seed and are potent trypsin inhibitors. They are members of the 
wider Knottin Family of mini-proteins [30, 31], which display exceptional stability due to 
their unique topology comprising three interlocked disulfide bridges. Knottins have shown 
great promise as scaffolds for the development of new drugs [32-36]. 
 
Notwithstanding the high affinity binding of MCoTI to trypsin, the neurotrophic effect of 
the seed extract appears unlikely to be mediated via the 7S NGF complex, since it is not 
present in the extracellular milieu of cultured PC-12 cells. Nevertheless, the above findings 
led us to consider that if MCoTI-II can bind to α- and/or γ-NGF, such that formation of the 
7S NGF complex is affected, the knottin could thereby modulate NGF activity. Of 
relevance to this idea, Blaber et al (1989) [37] compared the kinetic constants of γ-NGF 
and bovine pancreatic trypsin for several tripeptide substrates and found that γ-NGF 
exhibits the higher affinity for most of the substrates examined. Thus, MCoTI-II could 
have potential as the basis for a drug to modulate NGF levels in vivo by freeing β-NGF and 
allowing for it to have greater activity. To investigate this idea further, molecular modeling 
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and dynamics simulation were used to analyse the binding of a cyclic knottin trypsin 
inhibitor to γ-NGF.  
 
 
RESULTS AND DISCUSSION 
 
The crystal structure of MCoTI-II bound to bovine trypsin [29] was used as a template to 
dock MCoTI-II to γ-NGF, using the γ-NGF structure from the murine 7S NGF complex 
[11]. Coordinate alignment showed that 210 of trypsin’s 221 Cα atoms aligned with those 
of γ-NGF with an r.m.s. deviation of 1.02Å, indicating close structural similarity, as 
expected from the sequence alignment (Fig. S1). The structures differ mostly by the 
conformation of a number of loops surrounding the active site and the substrate-binding 
region. They differ significantly only in the region of the kallikrein loop [11], which 
contains an excision, and is longer in γ-NGF than the corresponding loop is in trypsin (Fig. 
S1). 
 
Figure 1 illustrates from a structural viewpoint how binding of MCoTI-II to γ-NGF can 
disrupt formation of the 7S NGF complex. Figure 1A shows the bound inhibitor in the 
context of the 7S complex, illustrating how it would sit within and prohibit normal 
interactions between γ-NGF and the C-terminal residues of both protomers of the β-NGF 
dimer. 
 
Figure 1B (left panel) shows a detailed view of the γ-NGF and β-NGF interaction site. C-
terminal residue R118 of β-NGF is bound within the S1 binding pocket of γ-NGF. 
Experiments have shown that R118 is required for formation of the 7S complex (Moore 
1974). Figure 1B (right panel) shows the MCoTI-II docked γ-NGF, illustrating how the 
inhibitor would interrupt the interaction of γ-NGF with the C-terminal residues of β-NGF. 
In particular, a lysine residue of MCoTI-II occupies the γ-NGF S1 binding pocket, thereby 
disallowing the essential interaction between γ-NGF and β-NGF R118. Of note, although 
γ-NGF was found to exhibit a pronounced preference for substrates with arginine rather 
than lysine at the P1 position with an order of magnitude difference in Km, γ-NGF 





From this structural alignment, starting coordinates for molecular dynamics simulations of 
MCoTI-II-bound γ-NGF were generated and a 300 ns simulation run to examine the 
stability of MCoTI-II bound to γ-NGF. Although the starting coordinates involved a 
number of steric clashes between ligand and receptor, these were mild enough that they 
could be relieved by a standard conjugate gradient minimization. This shows that there are 
no significant steric or structural impediments to the formation of the MCoTI-II-γ-NGF 
complex. 
 
Figure 2A depicts the time series of the r.m.s deviation of Cα atom coordinates from the 
initial structure. This shows that the MCoTI-II-bound γ-NGF complex is stable and 
becomes more so after an initial period where the ligand and receptor adjust to each other. 
To examine the stability of the ligand-receptor interaction further, Figure 2B depicts the 
time series of the distance between the geometric centres of MCoTI-II and γ-NGF during 
the simulation. This shows that the complex evolves toward a closer and less fluctuating 
interaction across the simulation. For comparison, Figure 2C shows the equivalent distance 
between MCoTI-II and trypsin from our previously reported simulation [38] that began 
with a crystal structure of the complex [29]. These data show that the MCoTI-II-γ-NGF 
complex evolves over 300 ns to an interaction closely similar in respect of its overall 
ligand-receptor distance to that observed in the simulation of the MCoTI-II-trypsin 
complex. 
 
Overall the modeling analysis presented here, support the hypothesis that natural knottin 
serine protease inhibitors within the extract could exert an NGF-mimetic effect by binding 
to γ-NGF and thereby shift the equilibrium between the active, free β-NGF and the inactive 
7S complexed form, toward the active form of the neurotrophic factor.  
 
Given that the seed protein induces neurite outgrowth in the absence of exogenous NGF, 
we evaluated if a synthetic recombinant protein of the same used in docking (MCoTI-II) 
could of itself induce NGF mimetic effects in PC-12 cells. The validity of the synthetic 
peptide sequence and purity (Figures 3A and 3B) were followed by biological studies 
which failed to show any neurite outgrowth over 7 days in PC-12 cells grown on collagen 
coated plates (Table 1). In conclusion, further research will be required to both identify the 









The starting coordinates for MD simulations were from the X-ray crystal structures of 
MCoTI-II bound to bovine trypsin (PDB 4GUX, chains A and D; [29]) and the γ-NGF 
subunit from the mouse 7S NGF complex (PDB 1SGF, chain G; [11]). To generate initial 
coordinates of MCoTI-II bound γ-NGF, the γ-NGF subunit was structurally aligned to 
MCoTI-II bound trypsin using Cα atom coordinates and the ‘iterative magic fit’ facility in 
SwissPDBViewer.  
 
The γ-NGF-MCoTI-II complex was solvated in a truncated octahedral periodic cell with a 
minimum of 20 Å between periodic images, and charge neutralised with a 0.2M NaCl 
solution. All histidine residues were neutral and protonated at the ε nitrogen, with the 
exception of the trypsin active site histidine 57, which was neutral and protonated at the δ 
nitrogen; all other ionisable residues were in the default ionization state. 
 
Simulation parameters 
MD simulations were performed using NAMD version 2.11 [39] with the CHARMM27 
force field [40], including φ/ψ cross-term map corrections [41], and the TIP3P model for 
water [42]. The SHAKE and SETTLE algorithms were used to constrain the bonds 
containing hydrogen to equilibrium length [43]. A cutoff of 12 Å (switching function 
starting at 10 Å) for van der Waals and real space electrostatic interactions was used. The 
particle-mesh Ewald method [44] was used to compute long-range electrostatic forces with 
a grid density of approximately 1/Å3(1/3 Å?). An integration time step of 2 fs was used 
with a multiple time-stepping algorithm; interactions involving covalent bonds and short-
range non-bonded interactions were computed every time-step, while long-range 
electrostatic forces were computed every two time-steps. Langevin dynamics was utilized 
to maintain a constant temperature of 310°K with a friction coefficient of 5 ps-1 on all 
non-hydrogen atoms. A Langevin piston was used to control pressure with a target of 1 
atm, a decay period of 100 fs and a damping timescale of 50 fs.  
 
Equilibration and Production Run 
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The solvated starting structure was minimized using 2000 steps of conjugate gradient 
minimization without restraints. The minimized structure was then heated from 50°K to 
310°K in steps of 25°K using velocity reassignment during a 30 ps MD run. The 
equilibrated system was used for the production run. The system was run without restraints 
for 150M integration steps equaling 0.3 µs of real time. 
 
Analysis 
VMD [45], Xplor-NIH [46] and Simulaid [47] were used to prepare the system and analyse 
MD trajectories. All structural figures were prepared using PyMol 
(http://www.pymol.org/pymol).  
 
Peptide Synthesis and Preparation 
The following protein, 1IB9, solution structure of MCOTI-II, from Momordica 
cochinchinensis was sequenced and verified for the recombinant expression construct by 
Raybio (Norcross, GA, USA). Prior to evaluation in vitro, the protein was dissolved in cell 
culture media at a stock concentration of 1mg/ml.  
 
 
Sequence: SGSDGGVCPK ILKKCRRDSDCPGACICRGNGYCG                   
Length 34 residues; Mass 3,477 Da. 
 
Cell Viability 
Alamar Blue cell viability assay was used to determine the potential cytotoxicity of 
MCoTI-II. Viable cells reduce a non fluorescent resazurin to resorufin, a fluorescence 
product. Briefly, 96-well collagen coated plates were seeded with PC-12 cells at a density 
of 0.5×106 cells/mL. Cells were treated with or without MCoTI-II for 7 days at 37°C, 5% 
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CO2. Alamar Blue (0.1 mg/mL in HBSS) was added at 15% v/v to each well and the plates 
were incubated for 6-8 h. Quantitative analysis of dye conversion was measured using a 
Synergy™ HTX Multi-Mode microplate reader (BioTek, Winooski, VT, USA), at 550 
nm/580 nm (excitation/emission).   
 
Neurite Outgrowth 
Neurite outgrowth was assessed by visual observation using an Zeiss standard bright field 
inverted microscope, with samples compared to a reference positive (7SNGF) 0.5 µg/mL 
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Figure 1.  
The 7S NGF complex and modelled γ-NGF-MCoTI-II interaction. Crystal structure of 
mouse 7S NGF complex (PDB 1SGF; [11] shown in ribbon representation. The protomers 
of the β-NGF homodimer are colored yellow and red, with C terminal residue β-NGF 
R118 shown in stick form in red (circled). One γ-NGF subunit is coloured green while the 
other γ-NGF and the two α-NGF subunits are colored pink, and as indicated. MCoTI-II is 
shown in surface representation in right panels and colored cyan. 
 
Panel A. Binding of MCoTI-II to γ-NGF in the context of the 7S complex. Left: Shows the 
7S complex with one β-NGF- γ-NGF interaction site circled. Right: Same view as left, but 
showing MCoTI-II docked to γ-NGF in relation to the complex. 
 
Panel B. Detailed view of β-NGF- γ-NGF interaction site. Left: Shows how C-terminal 
residues of β-NGF interact with the γ-NGF active site and substrate-binding region. Right: 
Same view as left, showing how bound MCoTI-II would sterically hinder the normal β-
NGF- γ-NGF interaction. 
 
Figure 2.  
Stability of MCoTI-II-γ-NGF complex during 300ns MD simulation. (A) Time series of 
the r.m.s deviation of Cα atom coordinates from the initial structure, sampled at 100 ps 
intervals. (B) Time series of the distance between the geometric centres of Cα atoms of 
MCoTI-II and γ-NGF, sampled at 100ps intervals. (C) Time series of the distance between 




(A) HPLC confirmation of purified recombinant MCoTI-II protein. (B) MS/MS 






































175	 ug/mL	 -	 -	
157.5	 ug/mL	 -	 -	
140	 ug/mL	 -	 -	
122.5	 ug/mL	 -	 -	
105	 ug/mL	 -	 -	
87.5	 ug/mL	 -	 -	
70	 ug/mL	 -	 -	
52.5	 ug/mL	 -	 -	
35	 ug/mL	 -	 -	
 
Table 1. Lack of efficacy for pure recombinant MCoTI-II protein to induce neurite 
outgrowth in PC-12 cells grown on collagen coated plates for 7 days. The data represents 
observational analysis for neurite outgrowth and toxicity, relative to negative and positive 
(NGF -7S from murine submaxillary gland) controls, n=3. There were no significant 
differences between the control groups and the MCoTI-II groups for neurite outgrowth or 





CLUSTAL O (1.2.4) sequence alignment of mouse γ-NGF with bovine trypsin. The N-
terminal 24 residues are removed by cleavage at γ-NGF R24 to create the active enzyme. 
The kallikrein loop in γ-NGF encompasses residues G100 to F112, with residues K108 to 
R111 being excised in the mature form. With the exception of the kallikrein loop, the 
sequences of the active enzymes align with only two single-residue gaps, at γ-NGF Y45 
and T232.  
 
 
 
 
